Oral tegafur in the treatment of gastrointestinal tract cancers: a phase II study.

Abstract

Fifty patients affected by histologically confirmed gastrointestinal tract cancer (GTC) were treated with oral tegafur (TG) 1,000 mg m-2 p.o. on days 1-14 repeated after a 14 day interval. Out of 42 evaluable patients seven patients had a partial response (PR. 17%) with a median duration of 20.5 weeks, three had a minimal response (7%) with a median… (More)
DOI: 10.1038/bjc.1990.105

Topics

5 Figures and Tables

Cite this paper

@article{Palmeri1990OralTI, title={Oral tegafur in the treatment of gastrointestinal tract cancers: a phase II study.}, author={Silvia Palmeri and Vittorio Gebbia and A. Russo and Michał Armata and Nicola Gebbia and Luciano Rausa}, journal={British Journal of Cancer}, year={1990}, volume={61}, pages={475 - 478} }